The annexes to Commission Implementing Decision C(2015) 3594 of 02 June 2015 concerning the work programme for 2015 in the framework of the third Programme of the Union’s action in the field of health (2014-2020) and the EU financial contribution to the WHO Framework Convention on Tobacco Control, serving as a financing decision set out the priorities and actions to be undertaken, including the allocation of resources (Annex I). The other annexes cover the eligibility, exclusion, selection and award criteria as well as criteria for assessing the independence from industry, commercial and business or other conflicting interests, and exceptional utility criteria (Annexes II to VIII). The allocation of resources (including EFTA) for the year 2015 is as follows: for grants (implemented under direct management): EUR 35 415 000; for procurement (implemented under direct management): EUR 16 423 805; for prizes (implemented under direct management): EUR 60 000 and for other actions: EUR 3 731 000. The total available budget is established at EUR 55 629 805 for 2015.

The full version of the annexes after adoption of the Work Programme 2015, will be available only in English and accessible at http://ec.europa.eu/health/programme/policy/index_en.htm

**ACTIONS PROPOSED FOR FUNDING (ANNEX I)**

Annex I of the Implementing Decision sets out the details of the various actions scheduled for 2015.

**GRANTS**

The total amount earmarked for this section is EUR 35 415 000.

- **Grants for projects**: Under the overall operational budget reserved for grants, EUR 9 000 000 are allocated to projects. The maximum rate for EU co-financing is 60 %. However, this may be up to 80 % if a proposal meets the criteria for exceptional utility set out in Annex VII. Annex II contains the eligibility, exclusion, selection and award criteria for project grants.

In 2015, the following actions are identified for funding:

- Gathering knowledge and exchanging best practices on measures reducing availability of alcoholic beverages;
- Early diagnosis and treatment of viral hepatitis;
- Early diagnosis of tuberculosis;
- Support for the implementation and scaling up of good practices in the areas of integrated care, frailty prevention, adherence to medical plans and age-friendly communities;
- Common assessment methodology on quality, safety and efficacy of transplantation therapies.

- **Grants for actions co-financed with Member State authorities:** EUR 17 850 000 will be reserved for grants for actions co-financed with Member State authorities. The maximum rate of EU co-financing is 60%. This may be up to 80% if a proposal meets the criteria for exceptional utility set out in Annex VII. Annex IV contains the eligibility, exclusion, selection and award criteria for these actions.

In 2015, the following actions are identified:
- Health Technology Assessment cooperation;
- Prevention of frailty;
- Market surveillance of medical devices;
- Rare cancer.

- **Financial contribution to the functioning of non-governmental body (Operating grants):** Under the overall operational budget reserved for grants, EUR 4 650 000 are reserved for operating grants. Operating grants are calculated based on eligible costs incurred. The maximum rate for EU co-financing is 60%. However, this may go up to 80% if a proposal meets the criteria for exceptional utility set out in Annex VII. Annex III contains the exclusion, eligibility, selection and award criteria for operating grants. Annex VI contains the criteria for assessing the independence from industry, commercial and business or other conflicting interests.

In 2015, no call for proposals will be organised as a result of the conclusion of framework partnership agreements (FPA) for a duration of maximum three years based on the work programme for 2014 – covering the operating years 2015, 2016, 2017. FPA recipients are eligible for a specific grant agreement. In 2015 they will be invited to submit an application for a specific grant agreement for 2016. This will include the annual work programme and the budget. Having received an FPA does not guarantee annual co-funding.

- **Presidency conference grants:** Presidency conferences, which are highly political in nature and involve representation at the highest national and European levels, are to be organised exclusively by the Member State holding the Presidency of the European Union. Two conferences organised by the Presidencies of the European Union may receive up to EUR 100 000 each, the maximum rate of EU co-financing being 50% of eligible costs incurred. The conferences supported under this work plan are a conference on ‘Personalised medicine’ planned under the Luxembourg Presidency and a conference on ‘Antimicrobial resistance’ under the Dutch Presidency.
**Direct grant agreements with international organisations:** The overall budgetary allocation reserved for actions implemented via direct grants to international organisations amounts to EUR 2 715 000. The maximum EU co-financing rate is 60 %, up to 80 % in case of exceptional utility. Funding for actions with international organisations will be allocated through grant agreements without a call for proposals on topics specifically identified in this work plan.

In 2015, activities supported will address:

- Economics of prevention (Grant to the OECD);
- EU Health Report 2016 (Grant to the OECD);
- Health workforce (Grant to the OECD);
- Antimicrobial resistance (Grant to the OECD);
- Data and analysis of data on patient safety, within the OECD ‘Health Care Quality Indicators’ Project (Grant to the OECD);
- The European Pharmacopoeia (Grant to the Council of Europe).

**Cross sub-delegation to Eurostat implemented through grants procedures:** The overall budgetary allocation reserved for these actions is EUR 1 000 000. Support will be given to actions related to morbidity statistics and non-expenditure health care statistics and will be implemented through grants, without a call for proposals. The beneficiaries will be the National Statistical Institutes and the other national authorities responsible for the development, production and dissemination of European statistics as designated by Member States.

In 2015, the maximum rate for EU co-financing may be up to 70 % due to the exceptional utility of the actions. Annex V contains the eligibility, exclusion, selection and award criteria for these grants.

**PRIZES**

The overall budgetary allocation reserved for prizes in 2015 amounts to EUR 60 000. In the context of the Health Policy Forum, a Health Award will be organized. The overall objective is to raise awareness of the vital role non-governmental bodies play in strengthening participative democracy and active citizenship for a healthier EU and fairer access to healthcare.

The award will reward and highlight good practices of international/European, national and/or sub-national non-governmental bodies which have made a significant contribution towards promoting a healthier EU and fairer access to healthcare for EU citizens, preventing diseases and protecting EU citizens’ health.
**PROCUREMENT**

For procurement (implemented under direct management), the total amount earmarked is EUR 16 423 805. It covers activities such as the evaluation and monitoring of actions and policies; studies; provision of advice, data and information on health; scientific and technical assistance; communication, awareness-raising and dissemination of results; and information technology applications in support of policies. Framework contracts and new service contracts will be used following tendering procedures for public procurement on TED. An overview of actions considered in this section is provided below:

- Tobacco and passive smoking;
- EU Health Policy Forum or similar cross cutting stakeholder activities;
- Surveys and target prevention projects for training of health professionals in the area of HIV/AIDS;
- Conceptual and structural work towards the development of a European approach on chronic diseases;
- Tobacco legislation - Provision of technical and scientific input and tailor-made tools to prepare and adopt cost-effective measures against smoking on the EU level, as well as to support the implementation of the existing policies;
- Capacity building against health threats in Member States;
- The role of public health law in the control of and protection against cross-border health threats;
- Public health preparedness and response training and exercises;
- Health innovation and e-Health: Use of e-Health and Big Data in Healthcare Policy and Research;
- Use of SNOMED Clinical Terms terminology for cross-border exchange of medical data;
- Support to prepare an Impact Assessment for the coordination of the HTA work;
- ESIF support in the area of health: building knowledge and capacities for monitoring and implementation, supporting innovation and effectiveness;
- Methodological improvements to international comparisons of the technical efficiency of the hospital sector;
- Maintenance and development of the existing EUDAMED;
- Development of the future EUDAMED following the adoption by the legislators of new Regulations on medical devices;
- Communication and publication actions to promote the understanding and correct implementation of the requirements and risks relating to medical devices;
- Clinical trials database;
• EMP database (management of marketing authorisations for medicinal products and of maximum residue limits of veterinary medicinal products) and IT systems;
• Evaluation of certain provisions and instruments under the pharmaceutical legal framework;
• Evaluation of the costs of the European Medicines Agency and the costs of the tasks carried out by the national competent authorities;
• Scientific and technical assistance for scientific committees, the Expert Panel on effective ways of investing in health and public health policies;
• Impact of health systems on health status of the population
• Health System Performance Assessment
• Implementation of Cross-border healthcare Directive and development of European Reference Networks;
• Preparatory work to set up a framework for a sustainable EU collaboration on patient safety and quality of care;
• Comparative assessment of the accessibility of healthcare services;
• Definition of a minimum basket of care for hospital patients;
• Development of open source software for the labelling of human tissues and cells for human application with the Single European Code (SEC).

Horizontal activities
• Communication, promotion and dissemination of information on EU health policies and the results of the Health programmes;
• Information technologies in support of public health policies;
• Mid-term evaluation of the Health Programme (2014-2020).

OTHER ACTIONS
The overall budgetary allocation for other actions in 2015 amounts to EUR 3 731 000. This section covers contributions paid by the EU as subscriptions to bodies of which it is a member, administrative agreements with the Joint Research Centre (JRC), system inspections on medicinal products, and special indemnities paid to experts for participating in meetings and for work on scientific opinions and advice on health systems.

Actions considered under this action will address:
• Technical and scientific support of the Joint Research Centre to action on Nutrition, Physical Activity and Alcohol-related harm;
• Risk assessment;
• Expert Panel on effective ways of investing in Health – Indemnities paid to experts;
• Technical and scientific opinions and advices regarding medical devices (administrative agreement with the JRC);
• Technical and scientific support for the development of a methodology for improving the operation of the medical devices field and for exploratory work on EU reference laboratories for medical devices (administrative agreement with the JRC);
• Reimbursement of experts’ expenses for joint assessments;
• Organisation and management of the meetings of the Medical Device Coordination Group (MDCG);
• EU experts in ICH – Development of EU requirements for the placing on the market of medicinal products for human use through the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human (ICH);
• Support of International Conference for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH);
• The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceutical for Veterinary Use (VICH) - reimbursement of experts' expenses;
• Active pharmaceutical ingredients: systems inspections;
• The Commission membership fee to the European Observatory on Health Systems and Policies; and
• Scientific Committees (indemnities paid to experts).